Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-3989 plus NA vs NA in chronic hepatitis D
CTR20210504Phase 2Terminated
- Sponsor
- Johnson & Johnson
- Start
- Mar 2021
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of tomligisiran in Chronic Viral Hepatitis B With Delta-Agent, Chronic Hepatitis B (CHB), sponsored by Johnson & Johnson. Started Mar 2021; status: terminated.
02
Drugs
tomligisiran
03
Conditions
Chronic Viral Hepatitis B With Delta-AgentChronic Hepatitis B (CHB)
Beyond the preview
Go deeper on CTR20210504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210504.